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1. ABSTRACT 
 
 Abstract (English) 
 Tuberculosis (TB) represents one of the major causes of mortality from an 
infectious disease. The bacillus Calmette-Guérin (BCG), a live attenuated strain of 
Mycobacterium bovis, is the only available TB vaccine despite it doesn’t protect against 
some forms of this re-emerging disease. Therefore, the development of a more adequate 
vaccine is essential for improving tuberculosis control. It has been suggested that the 
limited protection conferred by BCG is partly due to his missing expression of critical 
immunogenic proteins. Hence, it is conceivable that Mtb antigens not expressed by BCG 
strains could increase the efficacy of BCG vaccination. A recently proposed strategy to 
improve the efficiency of a vaccine formulation is the encapsulation of antigens into 
nanoparticles (NPs) that can avoid their rapid clearance by host organisms and can 
promote their capture by specific antigen presenting cells (APCs).   
On the basis of these premises and considering the key role played by human 
dendritic cells (DCs) in the defences against TB and, more generally, in vaccination, this 
thesis has been aimed at the discovery of new strategies, involving human DC mediated 
immune response, to improve the BCG effectiveness. 
 In particular, the study has been focused on two main goals: 
• investigation of the effects of Mtb antigens, HspX and ESAT-6, on human DC 
activity in order to verify their potential use as vaccine components (task A), 
• analysis of a vaccine nano-delivery system based on PLGA or pSi NPs to improve 
the capture of vaccine formulations by human DCs (task B). 
Task A. In this part of the study we found that the addition of HspX or ESAT-6 to 
BCG stimulated DCs does not affect DC maturation and pro inflammatory cytokine 
secretion. However DC stimulation with BCG and both HspX and ESAT-6 (BCG/HspX/ESAT-
6) greatly enhances the expression of DC maturation markers CD83, CD86 and MHCII, and 
induces the release of IL-12, TNF α, IL-6, IL-23 and IL-1β from these cells. 
Interestingly, DC treatment with BCG/HspX/ESAT-6 improves the ability of these 
cells to elicit IFN-γ release and CD69 expression by CD4+ lymphocytes and NK cells as 
compared to DC treatment with BCG alone or with BCG plus a single antigen. Moreover, 
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a TLR2-blocking antibody decreases IL-12 release by DCs stimulated with BCG/HspX/ESAT-
6, as well as IFN-γ secretion by CD4+ lymphocytes co-cultured with these cells. 
Furthermore, HspX and ESAT-6 improve the capacity of BCG treated DCs to induce the 
expression of memory phenotype marker CD45RO in naïve CD4+ T cells. Our results 
indicate that BCG, HspX and ESAT-6 cooperate in enabling human DCs to induce a 
substantial T lymphocyte and NK cell mediated immune responses through TLR2-
dependent IL-12 secretion. Therefore our findings suggest that HspX and ESAT-6 
represent good candidates for improving the effectiveness of BCG vaccination.     
Task B. Considering their biocompatibility and their relevance in the scientific 
literature, two different types of NPs have been utilized: PLGA (poly (lactic-co-glycolic 
acid) and pSi (porous silicon). Our results show that at doses up to 0.2 mg, which are 
widely considered appropriate for in vitro DCs stimulation, both PLGA and pSi NPs do not 
affect human DC viability. However, at doses exceeding 0.4 mg, PLGA, but not pSi NPs 
induce DC apoptosis, indicating that pSi NPs are less toxic than PLGA NPs. Hence, the 
amounts of NPs used in our experiments have been chosen accordingly. In this part of the 
work we found that PLGA and pSi NPs are unable to modify per se the secretion of pro-
inflammatory cytokines IL-12, TNF α, IL-6 and IL-23 by both resting and LPS-stimulated 
DCs. Interestingly, a confocal microscopy analysis reveals that both PLGA and pSi NPs are 
ingested by human DCs. However, PLGA NPs are more efficiently internalized by DCs than 
pSi NPs, indicating that PLGA NPs could be a suitable tool to be used for targeting 
molecules into human DCs. 
Take together our results suggest a new vaccination strategy against TB based on 
i) the combination of BCG/HspX/ESAT-6 in order to stimulate the immune system, and ii) 
the use of PLGA NPs to target antigens into human DCs. 
 
Abstract (Italian) 
 La Tubercolosi rappresenta una delle principali cause di mortalità da malattia 
infettiva. Il bacillo di Calmette-Guérin (BCG), un ceppo vivo attenuato del Mycobacterium 
bovis, è l’unico vaccino attualmente disponibile per la tubercolosi, nonostante non 
protegga da alcune forme di questa malattia considerata riemergente. Pertanto, lo 
sviluppo di un vaccino più adeguato ed efficace è essenziale per migliorare il controllo 
della tubercolosi. E’ stato proposto che la limitata protezione conferita dal BCG possa 
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essere parzialmente dovuta alla sua mancata espressione di importanti proteine 
immunogeniche. Dunque, è concepibile pensare che antigeni del Mtb che non sono 
espressi dai ceppi BCG, possano incrementare l’efficacia della vaccinazione da BCG. Una 
recente strategia di vaccinazione proposta per aumentare l’effetto della formulazione di 
un vaccino è l’inserzione di antigeni in nanoparticelle (NP) che possono evitare la loro 
rapida distruzione da parte dell’organismo ospite e possono promuovere la loro cattura 
da parte di specifiche cellule presentanti l’antigene (APC). 
Sulla base di queste premesse e considerando il ruolo chiave svolto dalle cellule 
dendritiche umane (DC) nelle difese contro la TB e più in generale, nella vaccinazione, 
questa tesi è stata finalizzata alla scoperta di nuove strategie, coinvolgenti la risposta 
immunitaria mediata dalle DC, per migliorare l’efficacia della vaccinazione da BCG. In 
particolare, lo studio si è focalizzato su due principali argomenti: 
• Indagine degli effetti degli antigeni di Mtb, HspX e ESAT-6, sull’attività delle DC 
umane al fine di verificare il loro potenziale utilizzo come componenti del vaccino 
(task A), 
• Analisi di un nano-sistema di trasporto basato su NP di PLGA (acido polilatico co-
glicolico) o pSi (silicio poroso) per potenziare la cattura delle formulazioni 
vacciniche da parte delle DC umane (task B). 
Task A. In questa parte dello studio abbiamo scoperto che l’aggiunta dei singoli 
antigeni ESAT-6 o HspX alle DC stimolate con BCG non modifica né la maturazione di tali 
cellule né la secrezione di citochine proinfiammatorie. Tuttavia, la stimolazione delle DC 
con BCG e con entrambi HspX e ESAT-6 (BCG/HspX/ESAT-6), aumenta significativamente 
l’espressione dei marcatori di maturazione CD83, CD86 e MHCII, e induce il rilascio di IL-
12, TNFα, IL-6, IL-23 e IL-1β da queste cellule. Inoltre, il trattamento delle DC con 
BCG/HspX/ESAT-6 aumenta la capacità di queste cellule di indurre il rilascio di IFN-γ e 
l’espressione di CD69 dai linfociti CD4+ e dalle cellule NK rispetto al trattamento delle DC 
con solo il BCG o con il BCG e i singoli antigeni. Abbiamo anche visto che il trattamento 
con un anticorpo bloccante anti-TLR2 riduce il rilascio di IL-12 dalle DC stimolate con 
BCG/HspX/ESAT-6 ed anche la secrezione di IFN-γ da linfociti CD4+ cocoltivati con queste 
cellule. Inoltre, HspX e ESAT -6 migliorano la capacità di DC trattate con BCG di indurre 
l’espressione del marcatore del fenotipo “memory”, CD45RO nei linfociti T naive. I nostri 
risultati indicano che BCG, HspX e ESAT-6 cooperano per consentire alle DC umane di 
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indurre una sostanziale risposta immunitaria mediata dai linfociti T e delle cellule NK 
attraverso la secrezione di IL-12 TLR2-dipendente. Pertanto, i nostri risultati suggeriscono 
che HspX e ESAT -6 risultano essere due buoni candidati per migliorare l'efficacia della 
vaccinazione BCG . 
Task B. Considerando la loro biocompatibilità e la loro rilevanza nella letteratura 
scientifica, sono stati utilizzati due diversi tipi di NP: PLGA e pSi. I nostri risultati mostrano 
che a dosi fino a 0,2 mg , che sono ampiamente considerate appropriate per la 
stimolazione in vitro di cellule dendritiche, sia le NP di PLGA che di pSi non influenzano la 
vitalità delle cellule. Tuttavia, a dosi superiori a 0,4 mg , le NP di PLGA , ma non quelle di 
pSi, inducono apoptosi delle DC, indicando che le pSi sono meno tossiche rispetto alle NP 
di PLGA. Quindi, la quantità di NP utilizzate nei nostri esperimenti sono state scelte di 
conseguenza. In questa parte del lavoro abbiamo trovato che nè le NP di PLGA nè quelle 
di pSi sono in grado di modificare di per sé la secrezione di citochine pro-infiammatorie 
quali IL-12, TNFα, IL- 6 e IL-23 sia in DC non stimolate, sia in DC stimolate con LPS. È 
interessante notare come l'analisi di microscopia confocale abbia rivelato che sia le NP di 
PLGA che le pSi vengono ingerite dalle DC. Tuttavia, è stato possibile osservare che le NP 
di PLGA vengono più efficacemente internalizzate dalle DC rispetto alle pSi. Queste 
evidenze suggeriscono che le NP di PLGA potrebbero essere uno strumento adatto da 
essere impiegato per il trasporto di molecole all’interno di cellule dendritiche umane . 
 L’insieme dei nostri risultati, pone l’attenzione su una nuova possibile strategia di 
vaccinazione contro la TBC basata su i) la combinazione di BCG/HspX/ESAT-6 al fine di 
stimolare il sistema immunitario, e ii ) l'uso di NP di PLGA per indirizzare gli antigeni nelle 
cellule dendritiche umane. 
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2. INTRODUCTION  
 
 Dendritic cells 
 
Dendritic cells (DC) are professional antigen presenting cells (APC) that captures 
antigens and are able to stimulate T and B cells thus initiating a primary immune response 
[1].  DC were first seen as Langerhans cells (LC) in the skin in 1868, and in 1973 Steinman and 
Cohn recognized them as major cells of the immune system [2].  
When DC were first characterised, researchers noticed that high levels of major 
histocompatibility complex (MHC) class II molecules are expressed on their cell surface [3]. 
MHC class II molecules are the protein complexes that present antigenic peptides derived 
from the exogenous peptides internalised from the extracellular fluid by antigen-presenting 
cells [4]. In addition high levels of the costimulatory molecules CD86 and CD80 (also called 
B7.2 and B7.1) and CD40 are expressed on DC surface [5]. These membrane proteins are 
responsible for the full activation (through signal transduction pathways) and proliferation 
of T cells after they are first stimulated. The large quantities of these molecules on DC was 
immediately recognised to be responsible for the unique capacity of dendritic cells (among 
other professional antigen-presenting cells) to prime naïve T cells, as well as to stimulate all 
T cells extremely efficiently. DC expressing high levels of MHC class II molecules on their 
surface were isolated from several different tissues, suggesting that all DC constitutively 
initiate immunity in vivo. With time, however, it has become evident that dendritic cells are 
not always activated but also reside in tissues as inactive or “immature” cells [2]. 
DC have evolved to monitor the environment, detect pathogens and trigger T cell 
activation, providing a link between the innate and adaptive immune system. Therefore, 
they are present in tissues which are in contact with the environment: in skin [6] and airways, 
stomach and intestines[7, 8], in the interstitial spaces of many organs tissues [9], lymphoid 
and they can also be found in blood [10, 11].  
To maintain tolerance as well as immunity, “sentinels” in the periphery of the body 
that patrol the boundaries against foreign enemies are essential. DC have long spiky arms, 
called dendrites, hence the name “dendritic cells”. Dendrites enable DC to contact a large 
number of other cells at one time so confering a high surface-to-volume ratio. DC circulate 
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throughout the body looking to acquire antigens from other cells, proteins or other 
molecules belonging to invaders (e.g., bacteria, fungi, viruses, toxins, allergens) or normal 
self-antigens.  
DC in peripheral tissues are mainly found as immature dendritic cells with high 
paghocytic capacity. Immature DC are specialized in capturing and processing antigens to 
form MHC peptide complexes, yet they have little ability to activate T cells. Immature DC can 
release cytokines to communicate with other cells of the immune system. Various stimuli, 
such as tissue damage, inflammatory mediators, microorganisms and cytokines, cause the 
DC to mature and migrate into the blood and finally to the secondary lymphoid organs, 
where they can present their captured antigens to T cells (Figure 1)[12].  
This maturation process involves an ordered series of signal-dependent events that 
result in specific alterations of gene expression, intracellular protein targeting, secretion and 
organelle biogenesis. The morphology of mature DC differs from that of immature DC, 
mature DC have an irregular shape with many finger-like projections that increase its surface 
area to present more molecular structures for interaction with lymphocytes. These 
projections extend and retract from the cell body to provide motility. Mature DC have 
transformed so that they are no longer able to capture antigens but have increased antigen 
presentation. This increased antigen presentation results in potent stimulation of T cell 
immunity. For the mature DC to activate naïve T cells, secondary signals, such as 
costimulatory and adhesion molecules, are required to initiate a primary response. The 
adhesion molecules ensure T cell contact and the stability of the immunological synapse, 
whereas the costimulatory molecules (CD80, CD86) ensure T cell activation and amplification 
of the signaling process [13, 14].  Thus, the main function of the immature or tissue DC is to 
absorb and process antigens, while the mature DC presents the antigen [15] (Figure 1).  
The relative scarcity of dendritic cells (they represent only 0.1% of all leukocytes) 
makes it difficult to isolate them in large quantities and so an intensive effort was made to 
generate these cells in vitro from bone marrow precursors. Several laboratories have 
established protocols for the production of primary dendritic cells of mouse and human 
origin. These methods, which use precursor cells from various sources, have also underlined 
the importance of specific cytokines for dendritic cell differentiation. For example, 
granulocyte-macrophage colony stimulating factor (GM-CSF) is indispensable for the 
generation of dendritic cells from bone marrow precursors. In addition to GM-CSF, 
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interleukin 4 (IL-4) is required to generate dendritic cells derived from human blood 
monocytes as was originally shown by Federica Sallusto and Antonio Lanzavecchia [14, 16]. 
Monocyte-derived dendritic cells (moDC) are at this moment the easiest accessible 
“source” of human dendritic cells. These cells are generated in 5 days from monocytes 
cultures in the presence of GM-CSF and IL-4. At day 5 they lose CD14 which is a monocyte 
lineage marker and gain CD1a, considered as the classical monocyte-derived dendritic cell 
marker. “Classical” stimuli like lipopolysaccharide (LPS) can stimulate the “immature” moDC 
to produce factors such as IL-6, IL-8 and IL-12. In some respects, moDC do not show the same 
behaviour or capability as dendritic cells isolated ex vivo, but they are often used for 
research, as they are still much more readily available than genuine DC. Moreover, a review 
published by Serbina et al. showed the importance of circulating blood monocytes in 
supplying peripheral tissues with macrophage and dendritic cell precursor and, in the setting 
of infection, in contributing to immune defence against microbial pathogens [17]. 
Maturation of dendritic cells was first observed in vitro with Langerhans cells. Freshly 
isolated Langerhans cells needed two or three days in culture to acquire both the 
morphological features of dendritic cells and their immunostimulatory activity. Maturation 
therefore became the key event for dendritic cell function, allowing a population of dendritic 
cells to synchronise antigen capture, antigen presentation and migration to the lymph nodes 
[18, 19].  
In the past few years, several classes of molecules responsible for DC maturation have 
been characterised: bacterial products like LPS, viral products, inflammatory cytokines (such 
as IL-1β and TNF-α) and costimulatory receptor stimulation (such as CD40 ligand on T cells) 
[18]. So, the initiation of maturation results from the integration of signals from various 
origins. Although we have been talking about DCs maturation as if it is a homogenous 
process, recent reports suggested that combinations of various maturation stimuli might 
affect dendritic cell activity differently. The factors used to stimulate DCs in vitro have 
different impacts on gene expression patterns and on their potential to stimulate T cells. 
Taken together, DCs comprise a unique system of APC designed to capture antigens at the 
side of entry and then to identify cognate T cells to prime a specific immune response. 
Modulators of this critical defense system would be powerful tools to better control 
pathogenic DCs mediated processes. 
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Figure 1. DC maturation and effector cells activation. 
A) Resident DCs are activated and migrate to the draining lymph nodes upon pathogen binding in peripheral 
tissues. At the same time, monocytes are recruited into peripheral tissues. There, they rapidly differentiate to 
antigen-capturing DCs and upon maturation migrate to the draining lymph node carrying high levels of peptide-
MHC complexes and costimulatory molecules. By physical interaction through an immunological synapse, naïve 
T or B cells achieve stimulation and become committed to proliferate. Moreover DCs are able to activate natural 
killer cells. B) Sustained TCR stimulation by continuous contact with DC and polarizing cytokines (such as IL-12 
or IL-4) promote T cell differentiation and polarization, (e.g. Th1, Th17 or Th2) to nonlymphoid tissue-homing 
effector cells. 
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Dendritic cells can internalise large quantities of soluble or particulate antigen in a highly 
regulated fashion. Many microbes possess their own cell adhesion molecules, which enable 
them to infect cells, whereas DC can activate an actin cytoskeleton-driven uptake 
mechanisms called phagocytosis, upon binding of particulate ligands such as microbes to 
specific cell surface receptors. 
Two classes of cell-surface receptors mediate phagocytosis, opsonic and nonopsonic 
receptors. The first, Fc receptors, recognise serum components which are deposited on 
microbes and interacts with immunoglobulin and receptors which recognise complement. In 
contrast, nonopsonic receptors must themselves discriminate between harmless host cells 
and molecules or surfaces of potentially dangerous microbes. DC possess germline-encoded 
pattern recognition receptors (PRRs) that recognize and are triggered by evolutionarily 
conserved molecules essential to pathogen function, which are absent from the host. These 
so-called pathogen associated molecular patterns (PAMPs) are widespread. Bacteria possess 
an abundance of PAMPs, from cell wall components (LPS, lipoproteins, peptidoglycans, 
lipoarabino-mannan) to DNA containing unmethylated CpG motifs. Yeast and fungal cell 
walls have PAMPs in the form of mannans and beta-glucans, retroviruses have a genome of 
dsRNA, and protozoa express several unique immunoglycosylated proteins and lipids. 
Dendritic cells express at their surface widespread antigen receptors such as C-type lectin 
receptors (CLRs) and Toll-like receptors (TLRs). They activate signaling pathways that induce 
upregulation of costimulatory molecules, antimicrobial effector responses and inflammation 
upon recognition of PAMPs. Many of them also are internalized and carry antigens to the 
MHC class II presentation pathway.  
 
 Tuberculosis 
 
From the past to the resumption 
Tuberculosis (TB) is the leading cause of death in the world from a bacterial infectious 
disease. The disease affects 1.7 billion people/year which is equal to one-third of the entire 
world population and more than 8 million new cases are diagnosed each year. 
Mycobacterium tuberculosis is the etiologic agent of tuberculosis in humans, which 
are the only reservoir for the bacterium. The bacterium Mycobacterium tuberculosis is 
annually responsible for nearly 2 million deaths worldwide. Pulmonary TB is known since the 
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time of Hippocrates as phthisis, which is derived from the greek for “wasting away”. During 
the European Middle-Age, TB was most commonly found in children because of the bacillum 
spread by unpasteurized milk from infected cows. In 1680 F.F. Sylvius carried out anatomic-
pathologic studies in pulmonary nodules from TB patients, which he named “tubercula” 
observing their evolution to lung ulcers. In 1722, Dr. B. Marten proposed that TB could be 
transmitted through the “breath” of a sick person. Finally, in the 1882, Dr. Robert Koch 
isolated and cultured M. tuberculosis from crushed tubercles. In the following years, Dr. P. 
Ehrlich provided the basis to develop the Ziehl-Nielsen staining, which is an important tool 
to diagnose TB. Fifteen years after the isolation of the etiologic agent of human TB, the 
scientist-couple A. Calmette and C. Guerin isolated the bovine variant. After 39th passage in 
dispersed culture they observed a morphological variant which was avirulent in many animal 
models, moreover conferring a protection against subsequent challenges with virulent M. 
tuberculosis. The vaccine currently known as BCG has become widely used to combat TB, it 
relies on a prophylactic administration of live attenuated bacilli to children.  
In the mid 1980 a mixture of 4 antibiotics was introduced as a TB chemotherapy, since 
then the TB mortality rates were considerably reduced. Although vaccination and 
chemotherapy have been established to combat TB, epidemiological data indicate that the 
disease has been eradicated in developed nations, while in developing countries is a long 
lasting problem. Currently, the WHO (World Health Organization) indicate that there have 
not been great effects on the global problem since the time of Koch [20] 60. TB resumption 
can be attributed to several factors: such as the association with HIV, the aging of the world 
population, aerosol route of transmission amongst environments of human accumulation 
(such as prisons and hospitals), the increase of immigrants from developing countries to 
developed ones and the increased number of cases of multiple drug-resistant (MDR) TB [20]. 
The treatment requires a six to 12 month regimen with at least two antibiotics. Failure to 
complete the full course of drug therapy can lead to M. tuberculosis organisms that are 
resistant to one or more anti-tuberculosis drugs, severely limiting effective treatment 
options. 
So, more than a solved problem, TB has reemerged as a serious public health threat 
worldwide. For this reason, many worldwide organizations decide to fund “The Global Plan 
to Stop TB” which is a comprehensive assessment of the action and resources needed to 
implement the “Stop TB strategy” and make an impact on the global TB burden. Its goal is to 
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dramatically reduce the global burden of tuberculosis by 2015 by ensuring all TB patients, 
including for example, those co-infected with HIV and those with drug-resistant TB, benefit 
from universal access to high-quality diagnosis and patient-centered treatment. The strategy 
also supports the development of new and effective tools to prevent, detect and treat TB. 
 
The microrganism 
Within the genus Mycobacterium a number of species are grouped into complexes 
that include bacterial species with a high degree of genetic similarity as well as cause similar 
disease syndrome. 
Mycobacterium is a genus of Actinobacteria, given its own family, the 
Mycobacteriaceae. The genus includes pathogens known to cause serious diseases in 
mammals, including tuberculosis and leprosy. The Latin prefix "myco—" means both fungus 
and wax; its use here relates to the "waxy" compounds in the cell wall. Mycobacterium 
tuberculosis is a small, rod-like bacillus, obligate aerobe growing more successfully in tissue 
with high oxygen contenct such as lungs. M. tuberculosis is highly hydrophobic with a high 
lipid content in the cell wall. Because the cells are hydrophobic and tend to clump together, 
they are impermeable to the usual stains so they are classified as acid-fast Gram positive 
bacterium due to their lack of an outer cell membrane. M. tuberculosis divides every 15 to 
20 hours, extremely slowly compared to other bacteria, which tend to have division times 
measured in minutes (for example, E. coli can divide roughly every 20 minutes). It can 
withstand weak disinfectants and can survive in a dry state for weeks. Most mycobacteria 
are found in habitats such as water or soil. However, a few are intracellular pathogens of 
animals and humans.  
Mycobacterium tuberculosis, along with M. bovis, M. africanum, and M. microti all 
cause the disease known as tuberculosis and are members of the tuberculosis species 
complex. Each member of the TB complex is pathogenic, but M. tuberculosis is pathogenic 
for humans while M. bovis is usually pathogenic for animals. 
The genome of the H37Rv strain was published in 1998 [21, 22]. Its size is 4 million 
base pairs, with 3959 genes. 40% of these genes have had their function characterized, with 
possible function postulated for another 44%. 90% of complete genome sequences is highly 
conserved (there is no diversity between one set of genes from a range of clinical isolates). 
The genome contains 250 genes involved in fatty acid metabolism, with 39 of these involved 
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in the polyketide metabolism generating the waxy coat. Such large numbers of conserved 
genes shows the evolutionary importance of the waxy coat to pathogen survival. 
The cell wall structure of Mycobacterium tuberculosis deserves special attention 
because it is unique among prokaryotes, and it is a major determinant of virulence for the 
bacterium (Figure 2). 
 
 
Figure 2. M. tuberculosis cell wall.  
 
 
The cell wall complex contains peptidoglycan, but otherwise it is composed of 
complex lipids. Over 60% of the mycobacterial cell wall is lipid. The lipid fraction of M. 
tubeculosis's cell wall consists of three major components, mycolic acids, cord factor, and 
wax-D. Mycolic acids are unique alpha-branched lipids found in cell walls of Mycobacterium 
and Corynebacterium. They make up 50% of the dry weight of the mycobacterial cell 
envelope.  Mycolic acids are strong hydrophobic molecules that form a lipid shell around the 
organism and affect permeability properties at the cell surface.  Mycolic Acids are thought 
to be a significant determinant of virulence in M. tuberculosis. Probably, they prevent attack 
of the mycobacteria by cationic proteins, lysozyme, and oxygen radicals in the phagocytic 
granule. They also protect extracellular mycobacteria from complement deposition in serum. 
Cord Factor is responsible for the serpentine cording (chains of cells in smears made from in 
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vitro-grown colonies). Cord factor is toxic to mammalian cells and is also an inhibitor of PMN 
migration. Wax-D in the cell envelope is the major component of Freund's complete adjuvant 
(CFA). The high concentration of lipids in the cell wall of Mycobacterium tuberculosis have 
been associated with various properties of the bacterium, such as impermeability to stains 
and dyes, resistance to many antibiotics, to killing by acidic and alkaline compounds, to 
osmotic lysis via complement deposition and to lethal oxidations and survival inside of 
macrophages.  
 
M. tuberculosis antigens 
To better understand the differences between M. tuberculosis, M. bovis, and the 
various BCG daughter strains, their genomic compositions were studied by performing 
comparative hybridization experiments on a DNA microarray [23]. As compared with M. 
tuberculosis, the vaccine strain lacks an entire genomic region, known as RD1 (region of 
deletion-1) which is intact in virulent member of the M. Tuberculosis complex. The locus RD1 
contains region for secreted proteins such as ESAT-1 [24]. 10% of genome is highly variable 
and correspond to a family of sequences that encode low molecular weight proteins which 
are secreted by M. tuberculosis when is cultured in vitro.  
One gene family of particular interest encodes Esx proteins, immunodominant T cell 
antigen that are secreted by a delicate apparatus [25]. The locus Esx1 encodes two family 
members of originally unknown function, CFP-10 (culture filtrate protein 10 KDa) also called 
MTSA-10 (M. tuberculosis secreted antigens 10 KDa) and ESAT-6 (early secreted antigen 
target 6 KDa). Like all other bacteria, mycobacteria have essential general secretion 
pathways which function to deliver bacterial proteins into the host cell phagosome or cytosol 
and manipulate the host response to infection. These types of export pathways are usually 
encoded on so-called “pathogenicity islands”, regions of the genome that are associated 
with virulence. The likely functional equivalent of these systems, termed ESX-1, has recently 
been identified [25]. This newly identified protein secretion system is required for growth 
during M. tuberculosis infection. Since the identification of MTSA-10 and ESAT-6, several 
studies suggested that these proteins are important for virulence, and recently Hsu et al. has 
suggested a possible role of ESAT-6 such as a toxin able to directly lyse cellular membranes. 
ESAT-6 has been extensively studied in mice and human models [26, 27]. One of the first 
reports has demonstrated that ESAT-6 is a M. tuberculosis antigen recognized by T cells from 
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a high number of tuberculosis patients, thus suggesting a potential role as an antigen for 
detection of clinical disease [26]. ESAT-6 has also been proposed for the potential vaccine 
role in an experimental model. Vaccination by using ESAT-6 delivered in a combination of an 
adjuvant mix, elicited a strong ESAT-6-specific T-cell response and protective immunity 
comparable to that achieved with Mycobacterium bovis BCG [28]. MTSA-10 has been 
demonstrated to bind to the human macrophage surface and induce TNF-α and NO release 
[29]. Other studies with human monocytes and alveolar macrophages have described 
promotion of the intracellular replication of bacilli by TNF-α [30, 31], thus raising the 
possibility that TNF-α secretion induced by secreted mycobacterial antigens, may also serve 
as an evasion mechanisms for M. tuberculosis. In this paper they speculate that the 
regulation of macrophage TNF-α and NO production in tuberculosis patient by a soluble 
secreted antigen, might have an advantage to enable mycobacteria to affect a wider 
population of macrophages release [29]. Moreover, another article have shown the capacity 
of MTSA-10 to lead the differentiation of bone marrow cells to dendritic cells, in the absence 
of any growth or differentiation-inducing factor [32] . These DC expressed various typical DC 
markers and were able to mature, stimulate T cells and secrete cytokines, upon the use of 
classical maturation stimuli [32]. This results indicate a putative physiological role for MTSA-
10 and possibly mimic the early events that would ensue during an infection, wherein the 
differentiation of DC by secreted antigens of M. tuberculosis might be followed up by the 
release of bacteria from macrophages, and eventually leads to a down-regulation of pro-
inflammatory responses to mycobacteria.  
Antigen 85 complex (three highly related proteins of approximately 30 KDa) is a 
family of fibronectin-binding proteins involved in the mycobacterial cell wall biosynthesis 
[33]. It is a major secretory product in Mycobacterium tuberculosis and M. bovis BCG culture 
fluids and strongly immunogenic (able to cause antibody synthesis and T-cell-mediated 
reactions). This antigen amongst others have been used as potential DNA vaccine candidates 
[34, 35]. In the last years many efforts were made to improve TB vaccination: a gene-
modified DC-based vaccine expressing antigen 85A was developed, these DC were able to 
elicit a remarkable CD4 and CD8 immune response conferring protection from M. 
tuberculosis challenge in mice model [35]. Other investigators have tried to use a fusion 
protein of ESAT-6 and Ag85B [36] or vaccine-targeted DC [37]. Although many studies seems 
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to be promising, most of them are really preliminary, so they will tell us in few years the real 
efficacy for TB vaccination. 
One-third of the entire human population may be latently infected with dormant 
bacilli. Clearly this delay in appearance of the active disease only complicates an already 
difficult problem, and new strategies which will allow the eradication of latent organisms are 
required. Such strategies will arise only through an improved understanding of the 
mechanisms by which the tubercle bacilli remains viable for such extended periods.  
As an initial effort to characterize the metabolic changes which allow M. tuberculosis 
to remain viable for such extended periods of time, Yuan et al. sought to characterize 
proteins which may be specifically synthesized during late exponential and stationary phase 
growth in vitro [38]. They identified the 16-kDa antigen of M. tuberculosis (α-crystallin) and 
demonstrated that it is encoded by a gene that, among the members of the genus 
Mycobacterium, is present only in the slowly growing M. tuberculosis complex organisms. 
The antigen α-crystallin is specifically expressed during the transition to stationary phase and 
is related to the broad family of heat-shock proteins (HSPs). An examination of the α-
crystallin domain of the M. tuberculosis homolog reveals that although the sequence 
homology is not high, the mycobacterial HSP possesses functional similarities with the 
proteins in this family, the chaperone function. They were able to demonstrate that M. 
tuberculosis over-expressing this protein displayed an enhanced resistance to autolysis 
following the end of log-phase growth [38] . Although few studies have hypothesize the role 
of α-crystallin during infection, they failed to provide information directly related to 
persistence during latent infections [39, 40]. They do suggest that this protein may be 
induced in response to such stresses (substrate starvation, oxygen limiting condition, etc…) 
as are encountered during an infection. The ability to persist following log-phase growth is a 
common theme in bacterial metabolism.  
However, despite the large volume of data available on these antigens the 
fundamental question regarding their physiological roles at sites of infection has not been 
answered yet.  
 
 Current and novel approaches for Tuberculosis vaccine  
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Despite immense efforts in TB vaccine research we continue to immunize with 
Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine, which was approved for 
human use at the beginning of the 20th century. BCG was proposed as a live vaccine against 
TB by Albert Calmette and Camille Guérin only few years after the discovery of the 
intracellular pathogen Mtb as the causative agent of TB by Robert Koch in 1890. M. bovis 
BCG was generated after continual passaging of the parental M. bovis strain for 13 years (a 
total of 230 passages) in media containing bile, which resulted in an attenuated strain with 
reduced virulence in animals. BCG vaccine production started in 1927 that then led to 
generations of daughter BCG strains with different genomic composition [23]. BCG vaccine 
is administered worldwide as a single intradermal inoculation dose. 
The use of heat-inactivated or live attenuated pathogens was the preferred choice 
for many years in traditional vaccinology since they contain a vast array of antigens. Because 
of this, a broad and diverse immune response is induced resulting in protection against the 
pathogen. However, BCG vaccination affords only partial protection in humans. Infact, BCG 
protects against miliary TB and meningitis TB in infants, but fails to protect against 
pulmonary and latent TB in adults of both sexes and all ages, including children [41]. The 
variable efficacy of BCG, ranging from 0 to 80% in randomized control trials is attributed to 
a number of factors, including geographical location of human population, loss of virulence 
genes essential in protective immunity, an insufficient induction of CD8+ T cell response, 
exposure to environmental (non-tuberculous) mycobacteria or helminthic infection prior to 
BCG vaccination [42]. 
 
TB vaccines in clinical trials  
Due to protection conferred by BCG in childhood, current vaccines strategies in 
clinical trials are either focused on engineering BCG to be more immunogenic or boosting 
prior BCG vaccination with new vaccine regimens in the hopes of increasing protection. 
There are also a few new live vaccines being tested to entirely replace BCG due to the 
associated risk of infection with the viable vaccine in TB-HIV population [43]. 
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 Live mycobacterium-based vaccines  
New-generation mycobacterial vaccine vectors utilize current BCG as backbone to 
express known T-cell immunogens from virulent Mtb or mutants of BCG that are capable of 
escaping the phagosome to induce CD8+ T cell response are being tested as vaccine 
candidates. BCG shares many proteins in common with Mtb, however many of these 
proteins are not well recognized by vaccinated humans or animals. One such antigen is the 
molecule known as antigen 85 B (Ag85B), a major secretory protein produced by Mtb 
previously shown to induce protection to TB in mice and guinea pigs [44]. Although BCG 
produces this protein, little or undetectable immune response to this molecule is observed 
after vaccination. However, a recombinant BCG vaccine (rBCG30) overexpressing and 
secreting ∼5.5 fold more Ag85B than conventional BCG induced an order of magnitude 
greater immune response when compared to the parental BCG vaccine. A Phase I clinical 
trial with rBCG30 has been successfully completed [45]. Another interesting recombinant 
BCG-based vaccine is VMP1002 [46]. VMP1002 was engineered using specific properties of 
listeriolysin O, a secreted thiol-activated cholesterol-binding hemolysin from Listeria 
monocytogenes. This protein forms multimeric forms that allow engineered VMP1002 cells 
to escape from phagolysosomes (pH5.5) to the cytosol of the host, where the microbial 
vaccine antigens can be processed by the MHC Class I machinery and then presented to CD8+ 
T cells [47]. 
 
Booster vaccines to augment BCG immunity 
The rationale behind this strategy is to boost anti-TB immunity induced by prior 
vaccination with BCG. The goal is to continue implementing BCG immunization in neonates 
but subsequently boost at an older age with another TB vaccine regimen to augment 
immunity and protection afforded by prior BCG vaccination. Several booster vaccines could 
be used including recombinant viral poxviruses and adenoviruses vectors, which are highly 
immunogenic and currently being evaluated as vaccine delivery systems for HIV/AIDS and 
other diseases [48]. MVA85A is a replication-deficient vaccinia virus Ankara (MVA) used as 
delivery system for the mycobacterial anti- gen 85A, which augmented BCG-induced 
immunity in humans [49]. 
A replication-deficient strain of adenovirus used a delivery vector elicits high 
magnitude and functional CD4+ and CD8+ T cell responses to a vaccine candidate [50]. 
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Indeed the engineered Ad5Ag85A,  a recombinant adenovirus serotype 5 (Ad5) vaccine 
vector expressing the Mtb antigen 85A is currently being tested in a phase I safety and 
immunogenicity study in BCG-vaccinated and nonvaccinated healthy adults in Canada. 
Another variation of this vaccine uses a non-replicating adenovirus serotype 35 expressing 
anti- gens 85A, 85B, and TB10.4 and is in clinical trial under the name of AERAS-402 [51] 
(Abel et al., 2010). The advantage of Ad35 over other delivery viral vectors is the low 
frequency of anti-adenovirus neutralizing antibodies and low-levels of pre-existing immunity 
found in human 
Another strategy to boost BCG-induced immunity is to use protein based subunit 
vaccines as boosting agents. Subunit vaccines currently in clinical trials include 
Mtb72F/ASO1/ASO2A, which consists of a 72 kDa recombinant protein containing Mtb32 
(Rv1196) and Mtb39 (Rv0125) antigens previously shown to induce strong CD4+ and CD8+ T 
cells responses in laboratory animals but more importantly, in healthy, PPD-positive 
individuals [52]. Another vaccine candidate in clinical trial is AERAS-44, which is a fusion 
protein called Hybrid 1 consisting of antigens 85B [47] and TB10.4 (Rv0288) [53]. The H1 
vaccine combined with adjuvants IC31, a synergistic combination of single stranded 
oligodeoxynucleotide and a peptide (KLKL5KLK) that induces the Toll-like receptor-9 (TLR9) 
had promising preclinical data in that the vaccine elicited Th1 responses and increased 
protection against Mtb in mice [54]. H56-IC3 is another candidate vaccine in early human 
trials. This promising vac- cine formulation contains novel latency-associated TB antigen, 
Rv2660c, along with Ag85B, ESAT-6, and the IC31 adjuvant [55]. 
 
DCs as a target for nanotechnology applications 
 
Given the peculiar characteristics of DCs as professional antigen presenting cells, it 
became clear that targeting nanoparticles (NPs) to DCs provides a promising strategy for 
improving immune response in certain conditions. In fact, NPs can modulate the immune 
response and might be potentially useful as effective vaccine adjuvants for infectious disease 
and cancer therapy. Although there is no accepted international definition for NPs, it is 
generally assumed that NPs are particles having one or more structural features on a scale 
of less than 100 nm that cause their properties to be different from that of the bulk material 
[56]. 
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A wide variety of NPs can be designed with particular properties (certain size, shape, 
and composition) to be used as vehicles for specific DC targeting. There are different 
strategies to use NPs as effective vehicles, such as NPs conjugated to antigens, which are 
recognized by specific receptors, antigens encapsulated within NPs, which offer the ability 
to protect the antigen from degradation and labeled NPs, which are also recognized by 
specific receptors and permit an effective tracking of their migration (Figure 3). These 
different strategies can be exploited for a variety of applications such as cancer 
immunotherapy and vaccines that manipulate the immune system for therapeutic benefits 
and minimize adverse effects. Tracking is also an important application that can be used to 
evaluate the correct migration of the NP to its target. Figure 3 summarizes the applications 
of DCs in immunotherapy that can be further exploited by the interactions with different 
engineered NPs, particularly dendrimers, polymeric NPs, metallic NPs, magnetic NPs, and 
quantum dots [56]. The electronic and optical properties and the chemical reactivity of small 
clusters are completely different from the better known property of each component in bulk 
or on extended surfaces. This is because a NP has a large surface area in relation to its size 
and is consequently highly reactive. For this reason the appropriate NP must be designed to 
be used as an effective vehicle that interacts correctly with DCs, so as to finally develop a 
desired response. 
 
 Mechanisms of action mediated by the interaction between DCs and NPs 
NPs conjugated with groups that permit specific recognition of DCs allow a more 
precise localization of these cells. This active targeting is based on the use of a wide variety 
of ligands such as antibodies, polysaccharides, peptides, and drugs that bind to a protein, for 
example a cell surface receptor. Another way to target DCs is by cellular uptake, capturing 
the NPs via endocytocis or pinocytosis [57, 58]. 
An efficient delivery avoiding cytotoxicity during passage through the DC membrane 
must be arranged to reach the intracellular compartment. For this reason, various 
biomaterials such as liposomes, polymeric NPs, and quantum dots, among others, are being 
used to target specifically DCs and finally accelerate their maturation.  
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Figure 3. Dendritic cells (DCs) and nanoparticle (NPs) targeting.  
The use of multifunctional nanosystems based on NPs (dendrimers, polymeric NPs, metallic 
NPs, magnetic NPs, and quantum dots) affords convergence of technologies (surface 
attachment, encapsulation, or labeled NPs) for simultaneous or sequential target-specific 
delivery of multiple drugs, antigens, or tracking molecules to DCs. The interactions involve 
the targeting of DC-specific receptors, and uptake of NPs through receptor-mediated 
endocytosis, phagocytosis, or macropinocytosis, so as to achieve a specific desired response 
in applications in the fields of vaccine research or cancer immunotherapy, where DCs are 
known to be key immune-based regulators. 
 
 
Precisely defined and engineered molecules with specifically designed functions can 
be attached to NPs and activate DCs Toll- like receptors (TLRs). An example of this strategy 
can be highlighted in the case of polyethylenimine-based small interfering RNA 
nanocomplexes (siRNA-PEI NPs), which activate specific TLRs expressed by tumor-associated 
DCs [59]. Other NPs are designed to avoid trafficking to degradative lysosomes, which are 
one of the most important cell barriers for effective gene transfer. Therefore, a high 
transfection efficiency can be achieved with NPs such as polymer nucleic acid complexes 
[60], used to prevent degradation. Moreover, most NPs are trapped in endosomes by 
receptor-mediated endocytosis. An example of an antigen carrier trapped in endosomes is 
the methoxypolyethylene glycol and poly (lactide-coglycolic acid) (PEG-PLGA) NP, which 
encapsulates a recombinant hepatitis B antigen able to react with an anti-HBs antibody [61]. 
Magnetic NPs have also been demonstrated by transmission electron microscopy images 
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and confocal microscopy to internalize DCs and localize mainly in the lysosomal 
compartment [62]. Other properties of the NPs such as the size that can have a significant 
effect on the endocytic process, have to be kept in mind. In particular the latter point has 
been investigated with magnetic NPs, and it has been concluded that endocytosis is not size 
selective within a size range of 10-200 nm [62]. Other data about size selective targeting of 
DCs with polystyrene NPs have been reported to show that large particles (500-2000 nm) 
traffic to the lymph nodes in a DC-dependent manner, whereas small NPs (20-200 nm) and 
virus-like particles drain freely to the lymph nodes, where they are taken up by lymph node 
resident DCs and macrophages [63]. 
An alternative strategy to specifically activate DCs can be carried out indirectly, by 
interacting with other cell types. This is the case of natural killer T (NKT) cells, which display 
potent antiviral and antimetastasis function after activation of DCs [64, 65]. For this reason, 
α-galactosylceramide (a glycolipid antigen presented by CD1d receptors on NKT cells) 
functionalized NPs are an attractive DC-mediated immunomodulatory strategy. The NKT 
cells, thus stimulated by TCR signaling, may finally activate DCs by upregulating co-
stimulatory molecules and intracellular trafficking via the MHC class I pathway. 
Take together these evidences suggest that NPs, for their ability to bring both 
antigens and adjuvants into cells, have a great potential as targeting systems for cancer 
vaccines.  
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3. AIM OF THE STUDY 
 
The main purpose of this thesis has been to design and characterize on the 
immunological point of view a new vaccine strategy that could be useful to fight TB, a 
reemerging disease. The relevance of this study is underlined by the awareness that 
despite TB is the leading cause of death in the world from a bacterial infectious disease, 
the vaccine currently used, known as BCG, does not confer an effective protection against 
various forms of the disease, especially adults pulmonary TB.  Hence, it is clear that the 
development of new and effective tools to prevent and/or treat TB is urgently needed.  
Considering the key role played by DCs in the defense against TB and in vaccination 
in general, the present study has been aimed at the discovery of new strategies to 
improve the human DC-mediated immune response against Mtb. In this regard, the focus 
of the research presented herein has been not only the investigation of the effects of new 
Mtb antigens useful as vaccine components on DC activity (Task A), but also the analysis 
of a vaccine nano-delivery system that could improve the capture of vaccine formulations 
by DCs, increasing the immune response mediated by these cells (Task B). 
 
Task A: analysis of ESAT-6 and HspX as new BCG adjuvants.   
BCG induces a good protection against TB in childhood, but is poorly efficient in   
some forms of this disease in adults. For these reasons the research on TB vaccination 
field is mainly aimed to ameliorate the protection conferred by BCG, either by engineering 
more immunogenic BCG formulations, or by boosting prior BCG vaccination with new 
adjuvants. However, there are also a few new-line vaccines being tested to entirely 
replace BCG. The limited efficacy of BCG vaccination against some forms of TB is partly 
due to the missing expression of critical immunogenic proteins. Among these, ESAT-6 and 
HspX have been found to be good immune-modulatory agents in various animal models, 
but their effects on human immune cells and, most importantly, their potential role as 
vaccine components has not been completely elucidated.  
On the basis of these premises, the first task of the investigations reported here 
has been to analyze whether the single or combined addition of ESAT-6 and HspX to BCG 
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could improve the human DC-mediated immune response and could induce a better 
immunological memory than the one elicited by BCG alone.   
 
Task B: Designing and testing an efficient nano-delivery system for human DC targeting. 
 
The development of delivery systems able to target various molecules toward 
immune cells could play a critical role in the future of vaccinology, and this is the reason 
of the emerging attention on nanoparticles as potential carriers of various molecules. 
Regarding the design of vaccine formulations, the encapsulation of antigens into 
nanoparticles can avoid their rapid clearance by host organisms and can promote their 
capture by a specific APCs. Hence, the selective targeting of vaccine formulations into DCs 
would be a valuable strategy to improve the immune response mediated by these cells. 
Various kinds of materials can be used for nanoparticle production. However, on the basis 
of their biocompatibility and their relevance in the scientific literature, two different types 
of nanoparticles have been utilized in this study: PLGA (poly (lactic-co-glycolic acid) and 
pSi (porous silicon). 
 The purpose of task B has been to design and to test a pSi or PLGA nanoparticle-
based delivery system able to selectively bring vaccine components into DCs improving 
the antigen capture by these cells and consequently, the immune response. 
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2. MATERIALS AND METHODS 
 
Reagents and antibodies 
The following reagents were used for DC preparation and stimulation: RPMI 1640 
and low-endotoxin fetal bovine serum (FBS) were obtained from Lonza (Walkersville, 
MD); recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) 
and human IL-4 were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany); 
gamma-irradiated whole cells of M. tuberculosis (strain H37Rv) were obtained through 
BEI Resources, NIAID, (NIH NR-14819); α-crystallin (Gene Rv2031c), a purified native 
protein from M. tuberculosis (strain H37Rv, NR-14860) was provided by NIH Biodefense 
and Emerging Infections Research Resources Repository, NIAID, NIH; M. bovis BCG kindly 
provided by Dr. G. Batoni (Dept. Of Experimental Pathology, Medical Biotechnology, 
Infectivology and Epidemiology, University of Pisa, Italy) was prepared as described in  
[66] and killed at 55°C for 30 minutes; rdESAT-6 was provided by Statens Serum Institut 
(Copenhagen, Denmark); ultrapure lipolysaccharide (LPS) from E. coli (0111: B4 strain) 
and palmitoyl-3-cysteine-serine-lysine-4 (Pam3CSK4) were purchased from InvivoGen 
(San Diego, CA). All of the above reagents contained less than 0.125 endotoxin units/ml, 
as measured by the Limulus amebocyte lysate assay (Microbiological Associates, 
Walkersville, MD).  
Flow cytometric analysis of surface marker expression and cytokine intracellular 
staining was performed using the following mouse anti-human antibodies: CD83 (HB15e), 
CD4 (SK3) and CD1a (HI149) (Becton Dickinson, San Jose, CA); CD56 (HCD56), CD69 (FN50), 
CD86 (T2.2), HLA-DR (L243) and IFN-γ (4S.B3) (Biolegend, San Diego, CA); CD4 (VIT4), 
CD45RO (UCHLI), CD45RA (T6D11) (Miltenyi Biotec); IL-17AF (20LJS09) (eBioscience, San 
Diego, CA). In the viability assays the percentage of apoptotic cells was determined using 
the Annexin V staining kit (Miltenyi Biotec). 
The following blocking antibodies were used in our experiments: anti- Toll-like 
Receptor (TLR) 2 (T2.5) (eBioscience, San Diego, CA); anti-IL12p70 (20C2) [67, 68] kindly 
provided by Dr. G. Trinchieri (Center for Cancer Research, NCI, Frederick, MD). 
Monoclonal mouse IgG1 (eBioscence) was used as the isotype control antibody. 
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PLGA nanoparticles (PLGA NPs) have been synthetized and characterized by the 
group of Professor U. Monaco (Biocrystallography Lab, Dep. of Biotechnology, University 
of Verona, Verona, Italy). Silicon nanoparticles (pSi NPs) have been synthetized and 
characterized by the group of Dr. N. Daldosso (Fluorescence Lab., Dep. of Computer 
Science, University of Verona, Verona, Italy). 
 
Preparation and culture of DCs, lymphocytes and NK cells   
After written informed consent and upon approval of the ethical committee, buffy 
coats from the venous blood of normal healthy volunteers were obtained from the Blood 
Transfusion Centre of the University of Verona. Monocytes were isolated from buffy coats 
by Ficoll-Hypaque and Percoll (GE Healthcare Life Science) density gradients and purified 
using the human monocyte isolation kit II (Miltenyi Biotec), as previously described [69]. 
The final monocyte population was 99% pure, as measured by FACS analysis. To generate 
immature DCs (iDCs), monocytes were incubated at 37°C in 5% CO2 for 5-6 days at 1 x 
106/ml in 6-well tissue culture plates (Greiner, Nürtingen, Germany) in RPMI 1640, 
supplemented with heat-inactivated 10% low endotoxin FBS, 2 mM L-glutamine, 50 ng/ml 
GM-CSF, and 20 ng/ml IL-4. The final DC population was 98% CD1a+, as measured by FACS 
analysis. 
To perform the experiments regarding the task A, DCs were treated for 24 hrs 
with: Mtb (50 μg/ml), Pam3CSK4 (10 μg/ml), LPS (100 ng/ml), BCG (50 μg/ml) alone or 
combined with HspX (10 μg/ml) and/or ESAT-6 (10 μg/ml). In the experiments performed 
with blocking antibodies immature DCs were pre-incubated for 15 min at room 
temperature with anti-IL-12p70, anti-TLR2 antibodies or an isotype antibody IgG1.  
To perform the experiments regarding the task B, iDCs were treated for 24 hrs 
with various doses of particles or, when necessary, with 100 ng/ml LPS. 
NK cells and autologous total and naïve CD4+ T cells were isolated from the 
lymphocyte fraction of the Percoll gradient with EasySep™ Negative Selection Human Cell 
Enrichment kits (StemCell Technologies, Vancouver, Canada). The final populations were 
98% pure, as measured by FACS analysis. To preserve T cells during differentiation of 
monocytes into DCs, the cells were spinned down, resuspended in freezing medium (low 
endotoxin FBS + 10% DMSO), and kept in a liquid nitrogen freezer. In order to study their 
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effects on T lymphocytes, mature DCs were co-cultured for 7 days with total CD4+ T cells, 
or for 9 days with naïve CD4+T cells. The DCs:T-cell ratio was 1:10.  
NK cells were incubated for 24 hrs with conditioned media (added to 1:1 ratio) 
from DCs treated with Mtb (50 μg/ml) or BCG (50 μg/ml) alone or combined with HspX 
(10 μg/ml) and/or ESAT-6 (10 μg/ml). For the experiments with blocking antibodies, the 
supernatants were pre-incubated for 15 minutes at room temperature with anti-IL-12p70 
and with an isotype antibody IgG1. 
 
ELISA assay 
The quantification of cytokine production in the cell culture supernatant was 
determined by specific Enzyme-Linked ImmunoSorbent Assay (ELISA). The Ready-Set-Go 
ELISA kits purchased from Bioscience (San Diego, CA) were used to assay the protein levels 
of: IL-12 (range 4-500 pg/ml), IL-23 (range 15-2000 pg/ml), TNF-α (range 4-500 pg/ml), IL-
6 (range 2-200 pg/ml), IL-1β (range 4-500 pg/ml), IL-10 (range 2-300 pg/ml), IFN-γ (range 
4-500 pg/ml), IL-17AF (range 30-4000 pg/ml) according to the manufacturer’s protocol. 
 
Flow cytometric analysis 
To perform cell surface protein staining experiments, the cells were washed twice 
with PBS salt solution and incubated for 30 min with 10% human serum to prevent non-
specific binding. For direct immunofluorescence staining, mouse anti-human CD1a, CD83, 
CD86, HLA-DR, CD69, CD56, CD4, CD45RO, and CD45RA were used (see reagents).  
To perform a cytokine intracellular staining, the T cells were treated with 20 ng/ml 
PMA, 1 μM ionomycin and 10 μg/ml brefeldin A (Biolegend) during the final 6 hrs of 
culture [70]. After staining with a fluorescent-conjugated antibody anti-CD4, the cells 
were incubated with fixation/permeabilization buffer (420801 and 421002, Biolegend). 
Subsequently, they were stained with anti-IL17AF and IFN-γ fluorescent-conjugated 
antibodies (see reagents). The percentage of apoptotic cells was determined using the 
Annexin V (see reagents). Samples were acquired on a seven-color MACSQuant Analyzer 
(Miltenyi Biotec) and FlowJo software (TreeStar, Ashland, OR, USA) was used for data 
analysis. 
 
Immunofluorescence and confocal microscopy analysis 
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DCs were seeded on 13 mm poly-L-lysine-coated coverslips; after treatment with 
NPs, the cells were washed with PBS and fixed with 4% paraformaldehyde (Sigma-Aldrich) 
for 30 min at room temperature and quenched with 50 mM NH4Cl. The cells were then 
permeabilized with PBS-0.1% Triton X-100 and blocked with 1% BSA for 30 min. After 
washing, the coverslips were incubated 30 min with Phalloidin-Rhodamine (Cytoskeleton, 
Denver, CO, USA) to visualize F-actin. In some experiments cells were also incubated for 
10 min with DAPI (Sigma-Aldrich) to stain nuclei. The cells were washed and mounted in 
glycerol based anti-fading medium. The images were acquired by confocal microscopy 
(Leica-Microsystems, Wetzlar, Germany) at 400× magnification by using the 63× oil 
immersion objective (1.25 NA). Z-stacks were acquired and the maximum intensity 
projections (MIPs) were obtained by using the LAS-AF software (Leica-Microsystems). The 
images were processed for brightness and contrast with Adobe Photoshop. 
 
Statistical analysis 
All the data presented are expressed as the mean + SD. The Statistical analysis, 
including Student’s t test and one-way ANOVA with Bonferroni test, were performed 
using SigmaStat 3.0 for Windows (Systat Software, San Jose, CA). 
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3. RESULTS AND DISCUSSION 
 
5.1 TASK A: analysis of ESAT-6 and HspX as new BCG adjuvants.  
 
RESULTS 
 
ESAT-6 and HspX improve the ability of BCG to stimulate human DC pro-inflammatory 
cytokine release and maturation  
It is well known that the interaction of DCs with pathogenic microorganisms or their 
derivatives elicits the production of various cytokines that orchestrate the immune 
response 34 [71]. In this regard, we first examined the capacity of BCG, ESAT-6 and HspX 
to induce cytokine secretion by DCs. For this purpose, monocytes purified from healthy 
donors as described in methods, were cultured for 5 days with GM-CSF and IL-4 to obtain 
immature DCs (iDCs). The latter cells were challenged with BCG, ESAT-6 or HspX, as well 
as with Mtb as a positive control [69]. After a 24 hr treatment, culture supernatants were 
collected and cytokine secretion was analyzed by ELISA. Preventive to their use, the 
amounts of bacteria and antigens have been chosen on the basis of previous dose-
response experiments.    
The apoptosis has been checked by using Annexin V staining. The concentration of 
bacteria and antigens used for the experiments described herein did not lead to any 
apoptosis events (data not shown).  
The ELISA assays revealed that BCG induced a weak release of various pro- and 
anti- inflammatory cytokines, as indicated in figure 1. Since the reintroduction of the 
ESAT-6 gene restores the ability of BCG to activate mouse immune cells [72], we wanted 
to determine whether the addition of the ESAT-6 protein, alone or simultaneously with 
HspX, which also augments the immune stimulatory effects of BCG in mice [73, 74] , could 
increase human DC response to BCG stimulation. As shown in figure 1 the addition of 
HspX alone to BCG-treated DCs did not significantly influence cytokine release, whereas 
ESAT-6 increased the secretion of IL-23 but not the other cytokines. Interestingly, the 
simultaneous addition of HspX and ESAT-6 to BCG-stimulated DCs significantly increased 
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the secretion of IL-12, IL-1β, IL-23, IL-6, and TNFα but not IL-10, as compared to DCs 
challenged with BCG alone or when combined with the single antigens (Fig. 4).  
It is important to note that DC challenge with a purified HspX and/or a 
recombinant ESAT-6 protein in the absence of BCG, did not induce any cytokine 
production from DCs (results not shown).  
 
 
 
 
Figure 4. Effect of HspX and ESAT-6 on BCG-induced cytokine secretion by DCs. 
Monocytes were treated (5 days) with 50 ng/ml GM-CSF and 20 ng/ml IL-4 to obtain immature DCs, that 
were subsequently cultured (24 hrs) in the absence (CTRL) or presence of 50 μg/ml BCG, alone or combined 
with 10 μg/ml HspX and/or 10 μg/ml ESAT-6. DCs were also cultured with 50 μg/ml Mtb as a positive control. 
Release of the indicated cytokines in culture supernatants was evaluated by ELISA. Results are expressed as 
the mean value + SD of seven independent experiments. Statistical analysis: DCs treated with BCG alone vs 
BCG plus HspX and ESAT-6 added alone or in combination; ns P>0.05, *P<0.05, **P<0.01, ***P<0.001. 
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DC maturation is another process that occurs when immature DCs interact with 
pathogens or their antigens. This process is accompanied by the above mentioned 
cytokine secretion and enables DCs to activate immune effectors cells [71]. This event 
leads to the formation of DCs with increased expression of CD83, CD86 and HLA-DR on 
the membrane surface [75, 76]. Therefore, in parallel to the cytokine detection, we 
checked the maturation state of the DCs already used for ELISA (Fig. 1), analyzing the 
membrane expression of CD83, CD86 and HLA-DR. We found that BCG did not induce 
significant CD83 and CD86 up-regulation and that it inhibited HLA-DR basal expression, as 
compared to untreated DCs (Fig. 5A and B). However, the simultaneous addition of ESAT-
6 and HspX to BCG-treated DCs significantly increased CD83, CD86, and HLA-DR 
expression, as compared to DCs incubated with BCG alone (Fig. 5A and B). Finally, we 
found that DCs did not mature upon cell stimulation with ESAT-6 or HspX in the absence 
of BCG, nor with BCG in the presence of single ESAT-6 or HspX (results not shown).  
 
ESAT-6 and HspX enable BCG-treated DCs to activate CD4+ lymphocytes  
Mature DCs are known to regulate the activity of T lymphocytes which play a 
prominent role in defensive mechanisms against tuberculosis. In particular DCs are 
involved in the polarization of various T helper (Th) populations, characterized by specific 
pro- or anti- inflammatory activity. The main pro-inflammatory Th subsets involved in the 
immune response against TB are Th1 and Th17 populations [77]. As we found that ESAT-
6 and HspX improved the BCG-dependent DC maturation and cytokine release (Fig. 4 and 
5), we hypothesized that these antigens could influence the capacity of DCs to regulate T 
lymphocyte activity. Therefore, we investigated whether treatment with BCG, HspX 
and/or ESAT-6 would enable DCs to induce Th1 and/or Th17 response. For this purpose, 
DCs induced to maturation with Mtb or BCG, alone or combined with ESAT-6 and/or HspX, 
were co-cultured with autologous CD4+ lymphocytes. After 7 days the culture 
supernatants were assayed by ELISA for the presence of IFN-γ and IL-17AF, secreted by 
Th1 and Th17 respectively. This time point was chosen on the basis of previous time 
course viability assays (results not shown). The figure 3A shows that DCs incubated with 
Mtb induced remarkable IFN-γ and IL-17AF production by T cells, whereas DCs stimulated 
with BCG, alone or in combination with either HspX or ESAT-6, showed a weak ability to 
activate these responses. However, DCs incubated with BCG and both HspX and ESAT-6 
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induced a significantly higher IFN-γ secretion by CD4+ lymphocytes than that elicited by 
DCs challenged with BCG alone or when combined with the single antigens (Fig. 6A). In 
contrast, IL-17AF secretion induced by DCs incubated with BCG/HspX/ESAT-6 was 
comparable to that observed when DCs were treated with BCG alone or in combination 
with either antigen separately. 
 
 
 
Among the classical Th1 and Th17 cells responsible for IFN-γ and IL-17 production, 
respectively, a Th17/Th1 subset able to produce both IL-17 and IFN-γ has been discovered 
[78]. In order to identify the T cell subsets responsible for cytokine production (Fig. 6A), 
we performed IFN-γ and IL-17AF intracellular staining. Cell viability was evaluated by 
Annexin V staining.  
Figure 5. Effect of HspX and ESAT-6 
on BCG-elicited DC maturation. 
DCs were treated with Mtb as a 
positive control and with BCG alone 
or combined with HspX and ESAT6. 
Cells were collected after 24 hrs 
culture and the expression of 
maturation markers was analyzed 
by flow cytometry. (A) Histograms 
illustrate CD83, CD86 and HLA-DR 
surface expression in CD1a+ cells 
and the MFI. Filled histograms 
represent the control, open 
histograms indicate treated cells. 
One of four different experiments is 
presented. (B) Bar graphs show the 
CD83, CD86 and HLA-DR MFI value 
of the four experiments expressed 
as fold change (MFI FC) over control 
(CTRL). Statistical analysis: CTRL vs 
BCG alone; BCG alone vs BCG plus 
HspX and ESAT6; ns P>0.05, 
*P<0.05. 
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Figure 6. ESAT-6 and HspX enable BCG-stimulated DCs to elicit IFN-γ secretion and to enhance CD69 
expression in CD4+ T lymphocytes 
DCs stimulated for 24 hrs with Mtb or BCG alone or with ESAT-6 and/or HspX, were co-cultured with 
autologous CD4+ cells for 7 days. (A) Evaluation of IFN-γ and IL-17AF secretion in culture supernatants by 
ELISA. Results are the mean + SD of seven experiments. Statistical analysis: DCs treated with BCG alone vs 
BCG plus HspX and/or ESAT-6; ns P>0.05, *P<0.05. (B) Evaluation of IFN-γ and IL-17AF production detected 
by intracellular staining and analyzed by FACS in Annexin V-/CD4+/CD1a- cells. Zebra plots illustrate one 
representative experiment and the percentage of positive cells (left); bar graphs show mean + SD of three 
experiments (right). Statistical analysis: DCs treated with BCG alone vs BCG plus HspX and/or ESAT-6; ns 
P>0.05, *P<0.05, **P<0.01. (C) FACS analysis of CD69 expression in Annexin V-/CD4+/CD1a- cells. Panels 
illustrating one representative experiment with the MFI are shown on the left. Filled histograms represent 
the control, open histograms represent treated cells. Bar graphs representing the MFI mean + SD of 
three experiments expressed as fold change over control (MFI FC) are shown on the right. 
Statistical analysis: DCs treated with BCG vs BCG/HspX/ESAT-6; **P<0.01. 
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The FACS analysis demonstrated that DC stimulated with BCG, alone or in combination 
with the single HspX or ESAT-6, showed a weak ability to induce Th1, Th17, and Th17/Th1 
differentiation, whereas DC incubated with BCG/HspX/ESAT-6 induced a remarkable 
development of all these Th cell subsets. (Fig. 6B). 
These results demonstrate that IFN-γ and IL-17AF, as detected by ELISA (Fig. 6A), 
are produced by Th1 and Th17, respectively, but also by Th17/Th1 cells. Although DCs 
incubated with BCG/HspX/ESAT-6 induced a significant increase in IL-17AF-producing cells 
as compared to BCG-treated DCs (Fig. 6B), the amount of IL-17AF detected in the culture 
media of these cells was not significantly different (Fig. 6A). This discrepancy could be due 
to the fact that a very low percentage of IL-17AF-producing cells is insufficient to generate 
significant IL-17AF protein secretion in culture media. 
We also performed control experiments with CD4+ lymphocytes stimulated with 
various combinations of BCG, ESAT-6 and HspX in the absence of DCs and we didn’t 
observe any IFN-γ or IL-17AF secretion (results not shown). This result suggests that BCG, 
ESAT-6 and HspX do not directly modulate T cell activation. Moreover, DCs alone treated 
with various combinations of BCG, HspX, and ESAT-6 did not secrete IFN-γ or IL-17AF 
(results not shown), thus ruling out their contribution to cytokine production after co-
culture of DCs with T lymphocytes.  
Subsequently, we analyzed the effect of BCG, HspX and ESAT-6 on the ability of 
DCs to induce the expression of CD69, a well-known T lymphocyte activation marker, in 
CD4+ cells [79]. We found that BCG-treated DCs did not elicit CD69 expression, whereas 
the simultaneous addition of BCG, HspX and ESAT-6 up-regulated this activation marker 
in CD4+ cells co-cultured with DCs. Notably, this effect was comparable to that obtained 
upon DCs challenge with Mtb (Fig. 6C). 
 
TLR2-dependent IL-12 secretion is involved in CD4+ lymphocyte activation by DCs 
stimulated with BCG, ESAT-6 and HspX   
It is well accepted that IL-12 plays a key role in the induction of IFN-γ secretion by 
T lymphocytes [80]. Hence, we hypothesized that among the cytokines secreted upon DC 
treatment with BCG/ESAT-6/HspX (see Fig 4), IL-12 could be the one mainly involved in 
the stimulation of IFN-γ secretion by T lymphocytes (see Fig 6). In this regard, we wanted 
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to examine whether IL-12 blockage could affect IFN-γ secretion. To test this hypothesis, 
the cells were incubated with an antibody able to bind IL-12p70 and, specifically, to block 
IL-12 without affecting IL-23 [67, 68]. The figure 4 shows that IL-12 blockage decreased 
the ability of DCs challenged with BCG, alone or combined with HspX and ESAT-6, to 
induce IFN-γ secretion by CD4+ lymphocytes. Moreover, the antibody treatment increased 
IL-17AF production by CD4+ lymphocytes cultured with DCs stimulated with 
BCG/HspX/ESAT-6 (Fig. 7). Similar results were obtained from control experiments with 
DCs incubated with the antibody and stimulated with Mtb. 
 
 
 
 
Figure 7. The ability of BCG, ESAT-6 and HspX-treated DCs to elicit IFN-γ secretion by CD4+ cell is mediated 
by IL-12 
DCs pre-incubated (open bars) or not (filled bars) with 20 µg/ml IL-12p70 blocking antibody were stimulated 
for 24 hrs with Mtb or with BCG alone or with ESAT-6 and HspX and then co-cultured for 7 days with 
autologous CD4+ T lymphocytes. IFN-γ and IL-17AF secretion was analyzed by ELISA. Results are expressed 
as the mean + SD of five experiments. Statistical analysis: antibody-treated vs antibody-untreated cells; ns 
P>0.05, *P<0.05.   
 
 
It is important to note that an isotype matched antibody did not affect the capacity 
of DCs to modulate the cytokine production by T cells (results not shown). These results 
indicate that ESAT-6 and HspX increase IFN-γ release by T lymphocytes mainly by 
enhancing IL-12 secretion by co-cultured DCs treated with BCG. Moreover, the ESAT-6- 
and HspX-dependent increase in IL-12 release inhibited IL-17AF secretion, shifting the 
lymphocytes toward a Th1 response characterized by a prevalent IFN-γ release. 
It has been reported that ESAT-6 [81, 82] and some Mtb heat shock proteins [83]  
bind TLR2, which plays a critical role in the interaction between DCs and mycobacteria 
[84]. Therefore, we explored whether a TLR2-blocking antibody could affect BCG, ESAT-6 
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and HspX cooperation. We found that the antibody reduced IL-12 release by BCG-treated 
DCs stimulated with ESAT-6 and HspX (Fig. 8A).  
 
 
 
The antibody also suppressed IL-12 release by both Mtb-treated DCs and control 
DCs stimulated with Pam3CSK4, a specific TLR2 agonist. In contrast, the antibody did not 
affect IL-12 production by DCs stimulated with LPS, a TLR4 agonist (Fig. 8A), indicating 
that it specifically blocks TLR2-dependent IL-12 release. Moreover, an isotype matched 
antibody did not affect IL-12 release by DCs stimulated with BCG/ESAT-6/HspX, Mtb, 
Pam3CSK4 or LPS (results not shown). Interestingly, the TLR2-blocking antibody also 
decreased the ability of DCs incubated with Mtb, as well as with BCG/HspX/ESAT-6, to 
induce IFN-γ secretion by co-cultured CD4+ lymphocytes (Fig. 8B). Additionally, the 
capacity to induce IFN-γ secretion by CD4+ lymphocytes was inhibited by the antibody 
only in Pam3CSK4-stimulated DC and not in LPS-treated DCs (Fig. 8B). 
 
DCs challenged with BCG, HspX and ESAT-6 induce a memory phenotype in naïve T 
lymphocytes 
Figure 8. TLR2 is involved in IL-12-dependent 
IFN-γ secretion by CD4+ cells co-cultured 
with ESAT-6, HspX and BCG-treated DCs.   
DCs cultured in the absence (filled bars) or 
presence (open bars) of 5 µg/ml TLR2-
blocking antibody were treated for 24 hrs 
with Mtb, BCG alone or combined with HspX 
and ESAT6, 10 µg/ml Pam3CSK4 (Pam3) or 
100 ng/ml LPS. (A) Supernatants were 
collected and IL-12 release was analyzed by 
ELISA. Results are the mean value + SD of four 
experiments. Statistical analysis: antibody-
treated vs antibody-untreated cells, ns 
P>0.05, *P<0.05, ***P<0.001. (B) DCs were 
co-cultured with autologous CD4+ T 
lymphocytes. After 7 days, culture 
supernatants were collected and analyzed by 
ELISA for IFN-γ release. Results are the mean 
+ SD of three experiments. Statistical analysis: 
antibody-treated vs antibody-untreated cells, 
ns P>0.05, *P<0.05. 
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One of the most important characteristics of a good vaccine component is the ability to 
induce an immunological memory that permits a rapid and efficient immune cell response 
in case of infection by its specific pathogen. Therefore, we wondered whether the 
treatment of DCs with BCG/HspX/ESAT-6 was able to induce a memory phenotype in 
naïve T cells. It is important to remind that human CD4+ lymphocytes extracted from the 
blood, contain both naïve and memory T cells. However, these two CD4+ T cell subsets are 
characterized by a different expression of CD45RO and CD45RA proteins on the 
membrane surface, that are considered specific memory and naïve T cells markers 
respectively. Therefore, the naïve CD4+ T cell subset is CD45RA+/CD45RO- while the 
memory subset is CD45RA-/CD45RO+ [85]. Using specific isolation kits based on these 
peculiar protein expression patterns, we have been able to separate from the blood only 
the naïve CD4+ T cell fraction. Subsequently, we co-cultured these naïve CD4+ T cells with 
DCs stimulated with BCG, alone or with HspX and ESAT-6, as well as with Mtb as a positive 
control. After 9 days, we analyzed by flow cytometry the expression of CD45RO and 
CD45RA.  
As shown in Figure 9A and B, BCG treatment did not lead to a significant expansion of 
CD45RO+ cells (22.9%), as compared to untreated cells (21.5%). Very interestingly, we 
observed that the simultaneous addition of HspX and ESAT-6 enabled BCG-treated DCs to 
induce the expansion of memory CD4+ T cell population (51.4%), as demonstrated by the 
up-regulation of CD45RO marker (Fig. 9A and B).   
 
ESAT-6 and HspX improve the ability of BCG-treated DCs to activate NK cells through 
induction of IL-12 release 
It is well known that the soluble mediators released by mature DCs after the 
interaction with pathogens activate various immune effector cells, including NK cells.  
Given the important role of NK cells in the host defence against micobacteria [86], we 
explored whether the cytokines released in culture supernatants by DCs in the 
experimental conditions depicted in Figure 4, induced NK cell activation. For this purpose, 
NK cells isolated from blood of healthy donors, were incubated with the conditioned 
media collected from the cultures of DCs already used for the ELISA assay described in 
figure 1. In these experiments DCs were treated with BCG, alone or combined with ESAT-
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6 and/or HspX, as well as with Mtb as a positive control for 24 hrs. Subsequently, the 
conditioned media were collected and used to stimulate cultured NK cells.  
 
 
 
After a 24 hr incubation, the IFN-γ secretion from NK was analyzed by ELISA, and the NK 
membrane expression of CD69 activation marker was evaluated by FACS analysis. We 
found that the incubation with media from Mtb-treated DCs induced IFN-γ release by NK 
cells (Fig. 10A), whereas culture supernatants from DCs stimulated with BCG, added alone 
or in combination with either HspX or ESAT-6, showed a slight ability to activate such a 
response (Fig. 10A). In contrast, media collected from cultures of DCs treated with 
BCG/HspX/ESAT-6 elicited a significantly higher IFN-γ release than that observed in the 
media from DCs incubated with BCG added alone or with the single antigens (Fig. 10A). 
The FACS analysis revealed that supernatants from DCs treated with Mtb or 
BCG/HspX/ESAT-6, but not with BCG alone, induced CD69 expression by NK cells (Fig. 
10B). Importantly, the direct NK cell stimulation with Mtb, BCG and antigens did not 
induce IFN-γ release or CD69 expression (results not shown), suggesting that in our 
Figure 9. CD45RO and CD45RA 
modulation in CD4+ naïve T cells.  
DCs pre-treated for 24 hrs with Mtb or 
with BCG alone or with HspX and ESAT6 
were co-cultured with purified CD4+ naïve 
T cells. After 9 days, the expression of 
CD45RO and CD45RA was analyzed by 
flow cytometry in AnnexinV-/CD4+/CD1a- 
cells. (A) Zebra plots illustrate one 
representative experiment with the 
percentage of CD45RO positive cells. (B) 
Bar graph shows the CD45RO and CD45RA 
MFI mean+SD of three experiments 
expressed as fold change over control 
(MFI FC). Statistical analysis: BCG vs 
BCG/HspX/ESAT-6, *P<0.05. 
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experimental conditions NK cell activation is mediated by soluble agonists released by 
mycobacteria- and antigen-activated DCs.  
 
 
 
Figure 10. Effect of BCG plus ESAT-6 and HspX on DC-mediated IFN-γ release and CD69 expression by NK 
cells. 
Culture supernatants of DCs treated as described in Figure 1 were incubated without (filled bars) or with 
(open bars) 20 µg/ml IL-12-blocking antibody and then added to purified NK cells. After 24 hrs, IFN-γ release 
was measured by ELISA (A and C) and CD69 expression was analyzed by flow cytometry in CD56+ cells (B). 
(A) Results are the mean + SD of three experiments. Statistical analysis: NK cells stimulated with 
supernatants from BCG-treated DCs vs supernatants of BCG plus HspX and/or ESAT-6-treated DCs; ns 
P>0.05, *P<0.05. (B) Panels illustrate one representative experiment and the bar graph shows the MFI mean 
value + SD of three experiments expressed as fold change over control (MFI FC). Filled histograms represent 
the control; open histograms represent the treated cells. Statistical analysis: NK cells stimulated with 
supernatants from BCG-treated DCs vs supernatants of BCG/HspX/ESAT-6-treated DCs, *P<0.05; (C) Results 
are the mean + SD of three experiments. Statistical analysis: IL-12-blocking antibody-treated supernatants 
vs untreated supernatants; ns P>0,05, *P<0.05.  
 
 
As IL-12 plays an essential role in the NK cell activation [87], we analyzed the effect 
of the IL-12-blocking antibody, already used for the experiments shown in Fig. 7, on NK 
cell responses induced by culture media of DCs stimulated with BCG and the two antigens. 
Antibody addition to the media from DCs treated with Mtb or BCG/HspX/ESAT-6 
decreased the ability of these supernatants to induce IFN-γ release by NK cells (Fig. 10C). 
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An isotype matched antibody did not affect the capacity of culture media from DCs 
treated with Mtb or with BCG/HspX/ESAT-6 to stimulate IFN-γ release by NK cells (results 
not shown). These results indicate that ESAT-6 and HspX enhance NK cell activation by 
increasing IL-12 release from BCG-treated DCs. 
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DISCUSSION 
 
In the first part of this work it has been found that BCG shows a scarce ability to 
induce human DC maturation and cytokine release, which results in a subsequent weak 
capacity of DCs to induce CD4+ lymphocytes and NK cell activation. These findings confirm 
previous data showing a weak immune cell response to BCG [88] which might, in part, 
explain why BCG vaccination does not produce strong and persistent protection against 
adult pulmonary tuberculosis. In this part of the research it has been also found that ESAT-
6 and HspX, per se or when separately added to BCG-treated DC, do not significantly affect 
DC activity. However, ESAT-6 and HspX cooperate in increasing BCG-dependent DCs 
maturation and pro-inflammatory cytokine secretion, suggesting that the addition of 
HspX and ESAT-6 could confer to BCG important immune stimulatory characteristics. 
Conversely, anti-inflammatory cytokine IL-10 secretion did not significantly increase, 
indicating that the cooperation between ESAT-6 and HspX results in a preferential release 
of mediators that enhance pro-inflammatory immune response. This indication is 
supported by the evidence that upon stimulation with both these antigens and BCG, DCs 
become able to activate CD4+ lymphocytes and NK cells. Interestingly, this treatment 
rendered DCs able to induce a memory phenotype in naïve T lymphocytes, further 
corroborating the suggestion that HspX and ESAT-6 enhance the ability of BCG to activate 
immune responses.  
Taken together these findings are very important considering that the ability to 
elicit immunological memory is an essential requisite of vaccine components. Moreover 
these data are consistent with previous reports that demonstrate as reintroduction of the 
ESAT-6 gene into BCG improves its capacity to protect mice against Mtb challenge [72]. 
It has been reported that the addition of HspX  [73] or ESAT-6 [26]  alone activates 
IFN-γ production by human PBMC. However these effects were obtained with cells from 
patients with tuberculosis, whereas healthy or BCG-vaccinated subjects were less or not 
responsive to HspX  [73] or ESAT-6 [26]. It is conceivable, therefore, that in the absence 
of Mtb infection, stimulation with either HspX or ESAT-6 alone does not efficiently 
activate immune cells and/or boost BCG-induced cell responses. The results reported so 
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far in the present work suggest that a more effective stimulation might be obtained by 
treating human immune cells from healthy subjects with BCG and both the antigens. 
It has been demonstrated that a recombinant DNA vaccine encoding ESAT-6 elicits 
a strong Th1 response in mouse models [89] 17, and that HspX-based vaccines enhance 
the ability of BCG to stimulate immune response [73] [90-92]. In the present study, 
however, neither ESAT-6 nor HspX alone activated immune cells on their own or when 
either was combined with BCG. This discrepancy indicates that, differently from murine 
cells, stimulation with both ESAT-6 and HspX is needed to induce human immune cell 
response.  
Conversely, the findings obtained during the performance of this task are in line 
with previous results showing that vaccination with fusion protein composed of two Mtb 
antigens efficiently increases DCs and T cell response [36, 37, 93]. Importantly, we 
observed that DCs are necessary for the activation of T lymphocytes and NK cells by Mtb, 
BCG and antigens. These data indicate that the effect of these agonists is mediated by 
DCs. A number of studies have suggested that DCs reinforce cellular immune response 
against Mtb. In fact, DCs are very well represented at the sites of Mtb infection, where 
they capture antigens, mature and migrate towards lymphoid organs in which they prime 
T cells through antigen presentation, cytokine secretion, and co-stimulatory molecule 
expression [94]. In this regard the results presented herein, corroborate these findings, 
highlighting the essential role of DCs in the mechanisms driving protective immunity 
against Mtb. In the present work we also report that conditioned media from DCs cultured 
with BCG and antigens activate NK cells, suggesting that soluble factors released by DCs 
are sufficient to activate NK cells. These results are crucial, given that NK cells are involved 
in the control of Mtb infection and activated by Mtb-treated DCs [86, 95]. Importantly, 
among the many soluble factors secreted in culture media, IL-12 produced upon 
stimulation of BCG-treated DCs with HspX and ESAT-6 plays a central role in both CD4+ 
and NK cell stimulation. These findings agree with previous studies showing that IL-12 is 
the most important cytokine for T cell and NK cell activation [87]. 
Here we also report that inhibition of IL-12 release leads to increased IL-17AF 
secretion by T cells cultured with DCs stimulated with BCG, HspX and ESAT-6. This results 
confirm previous findings that T cells shift from Th1 to Th17 production, depending on 
the type of cytokines present in the cell environment [78, 96]. In particular, IL-12 elicits 
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IFN-γ secretion [97], whereas other cytokines, such as IL-1β, IL-23, and IL-6, promote 
and/or maintain both IL-17A and IL-17F release [98-100]. Despite DC treatment with BCG, 
HspX and ESAT-6 induces a remarkable increase in IL-1β, IL-23 and IL-6 secretion, the 
enhanced IL-12 release, obtained in the same experimental conditions, pushes T cells 
toward a Th1 response and it inhibits Th17 response. This finding is remarkable because 
Th1 cells are known to play an important role in host defense against Mtb [101]. Although 
the role of Th17 in host protection against tuberculosis has not been completely clarified, 
it has been shown that the IL-23/Th17 pathway is not crucial for the control of Mtb 
infection [102]; therefore, the shift from Th17 toward Th1 response, induced upon HspX 
and ESAT-6 treatment, might increase the effectiveness of immune response against Mtb. 
Moreover, we identified a receptor involved in the effects of ESAT-6 and HspX on 
human DCs. Little is known about the receptors engaged by Mtb antigens. It has been 
demonstrated that ESAT-6 and some Mtb heat shock proteins bind TLR2 [81-83], which is 
involved in the interaction between DCs and mycobacteria [84]. Our results show that 
TLR2 plays an important role in the mechanisms by which Mtb, ESAT-6 and HspX induce 
IL-12 release and subsequent Th1 response. The formality of TLR2 recruitment during the 
coordinated action of BCG and mycobacterial antigens remains to be characterized. 
However, our results highlight that TLR2 participates in the biological events leading to 
the activation of immune defense against tuberculosis.  
In conclusion, in the first part of the study we found that HspX and ESAT-6 
cooperate to enhance the capacity of human BCG-primed DCs to produce IL-12 which, in 
turn, induces an effective Th1 and NK cell response. Moreover, the cooperation of HspX, 
ESAT-6 and BCG in IL-12 production occurs through TLR2 receptor engagement. 
Importantly, this is the first evidence that HspX and ESAT-6 improve the ability of BCG to 
stimulate human DC-dependent activation of T lymphocytes and NK cells, suggesting that 
these antigens could be used to increase the immune system’s responsiveness to 
vaccination with BCG. 
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5.2 TASK B: investigation of PLGA and pSi NPs as nano-delivery system for 
human DCs targeting. 
 
RESULTS 
 
Evaluation of PLGA and pSi nanoparticle toxicity on human DCs 
It is well accepted that to be suitable candidates for various biomedical purposes, 
nanoparticles (NPs) should not induce toxic effect and/or adverse immune reactions. 
Therefore, preventive to the use of PLGA (poly (lactic-co-glycolic acid) and pSi (porous 
silicon) NPs as BCG/ESAT-6/HspX carriers into DCs, we determined whether the NPs 
exerted per se toxic effects on these cells. For this purpose, iDCs prepared as previously 
described (see TASK A and methods) were challenged with different doses of PLGA or pSi 
NPs (kindly provided by Dr H. Monaco and Dr. N. Daldosso respectively). After a 24 hr 
treatment the cell viability was assessed by Annexin V staining and flow cytometric 
analysis.  
 
 
 
 
Figure 11. Effects of PLGA and pSi NPs on DCs viability 
DCs were treated with the indicated doses of PLGA (A) or pSi (B) NPs. After a 24 hour incubation, cells were 
stained with annexin V for the identification of apoptotic cells, and analyzed by flow cytometry. The results 
are expressed as the mean value + SD of three independent experiments.  
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As shown in figure 11A, the incubation with PLGA NPs at doses of 0.02, 0.08 and 
0.2 mg did not affect DC viability. However, at the highest dose used (0.4 mg) the 
percentage of alive DCs was about 50%, whereas that of control untreated cells was 80%, 
indicating that this amount of PLGA NPs was quite toxic (Fig 11A). On the bases of this 
evidence, the subsequent experiments involving PLGA NPs were performed using particle 
doses lower than 0.4 mg. Conversely, as depicted in figure 11B the incubation of DCs with 
doses of pSi NPs ranging between 0.25 and 1 mg did not lead to any DC apoptosis event. 
This is a very important point considering that 1 mg represents an extremely high dose 
for the in vitro stimulation of DCs. Moreover, a different pSi functionalization, consisting 
in the presence of NH2 or COOH groups at the NP surface, did not cause relevant changes 
of NP toxicity on DCs. This result underlines the possibility to expose various chemical 
groups at the NP surface in order to increase and/or maintain NP stability without 
enhancing their toxicity. 
 
Evaluation of PLGA and pSi nanoparticle effects on human DC activation 
The activation of DCs results in the production of various cytokines that stimulate 
the inflammatory process and the immune response [71]. Therefore it is important to 
assess whether nanostructures that have to be used for medical applications stimulate 
these cells causing inflammation and/or adverse immune reactions once injected in 
patients [103]. We then examined whether our NPs induce pro-inflammatory cytokine 
secretion by DCs. For these reasons iDCs were challenged with various doses of PLGA or 
pSi NPs for 24 hrs in absence or presence of LPS. Subsequently, the supernatants were 
collected and checked for the presence of the pro-inflammatory cytokines IL-12, TNF α, 
IL-6 and IL-23. As clearly shown in figure 12, the incubation of resting DCs with various 
doses of PLGA NPs (ranging between 0.02 and 0.2 mg) did not elicit any pro-inflammatory 
cytokine release by DCs and did not significantly affect the LPS-induced cytokine 
production. This finding indicates that the PLGA NPs synthesized following the protocol 
of Dr H. Monaco are unable to interfere per se with human DC activation mechanisms and 
therefore, they represent suitable tools to investigate the effects of NP-associated 
molecules on these cells. Similar results were obtained when DCs were treated with doses 
of pSi NPs ranging between 0.25 and 1 mg (results not shown). Hence, these NPs 
represent a promising tool for antigens delivery into human DCs. 
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Figure 12. Effects of PLGA NPs on DCs cytokine secretion 
iDCs were treated for 24 hours with the indicated concentrations of PLGA NPs in the absence (open bars) 
or presence (filled bars) of 100 ng of LPS. The release of the indicated cytokines in culture supernatants was 
evaluated by ELISA assay. The results are expressed as the mean value + SD of three independent 
experiments.  
 
 
Evaluation of PLGA and pSi nanoparticle internalization by human DCs 
In order to transport molecules into cells, it is important to choose a carrier that 
could be efficiently ingested by the cells. Hence, we investigated whether human DCs 
were able to internalize PLGA and pSi NPs. For this purpose human DCs were incubated 
with rhodamine B-coniugated PLGA NPs and after 24 hrs the NPs uptake by DCs was 
checked by confocal microscopy. This analysis revealed that NPs were efficiently 
internalized by human DCs (Figure 13). For example, Figure 13 panel B illustrates a single 
DC that ingested more than ten PLGA NPs. Moreover, the different z-stacks of the same 
TASK B: RESULTS AND DISCUSSION 
50 
 
field shown in panels C-E demonstrate that the particles are indeed localized inside the 
cells. 
 
 
 
Figure 13. PLGA NPs internalization by human DCs  
Confocal microscopy images of DCs treated with 500 µg of rhodamine B-coniugated PLGA NPs (red). After 
a 24 hour treatment the cells were fixed and stained with Phalloidin to label filamentous F-actin (green), 
and with DAPI to visualize nuclei (blue). One representative experiment of three is shown. (A) zoom-out 
and (B) zoom-out represent two different fields of individual experiments; (C-E) zoom-in of (A) represent 3 
different z-stacks of the same field: upper (C), middle (D) and lower (E). 
 
 
 Notably, we did not observe any extracellular particle in the examined fields, 
indicating that the NPs were effectively swallowed by DCs. These results demonstrate that 
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human DCs are able to internalize large amounts of PLGA particles and therefore these 
nanostructures represent good vehicles to carry molecules into the cells. Similar 
experiments have been done incubating DCs with pSi NPs for 24 hrs and analyzing the NP 
uptake by confocal microscopy. However in this case we exploited the intrinsic 
fluorescence of these NPs without the need of any fluorochrome conjugation. This 
analysis revealed that the pSi NPs were internalized by human DCs less efficiently than 
PLGA NPs (about 1 pSi/cell vs 10 PLGA/cell). For example, the figure 14A shows a confocal 
microscopy field in which yellow arrows indicate the pSi NPs-NH2 that have not been 
internalized by DCs. Conversely, in panel B is shown a zoom-in of the above field 
highlighting the only cell showing an ingested particle. These data have been confirmed 
by other experiments performed in the same experimental conditions. Moreover, similar 
results have been obtained using pSi NPs-COOH (results not shown), indicating that the 
presence of NH2 or COOH on pSi surface did not change the particle uptake by DCs. 
 
 
 
 
Figure 14. pSi-NH2 NPs internalization by human DCs  
Confocal microscopy images of DCs treated with 500 µg of pSi-NH2 NPs (green). After a 24 hour treatment 
the cells were fixed and stained with Phalloidin to label filamentous F-actin (red). One representative 
experiment of three is shown. (A) Internal z-stack of a general field; (B) a zoom-in of (A). 
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DISCUSSION 
 
In the second part of this work we tested the effects of PLGA and pSi NPs on human 
DCs. Our interest on these NPs is due to their characteristic biodegradability and their 
wide use for biomedical applications in humans [104, 105]. Moreover, the fact that PLGA 
is a FDA approved polymer and that pSi have intrinsic stable fluorescence [105] renders 
this NPs suitable tools as carriers of BCG/HspX/ESAT-6 into human DCs. First of all we 
decided to explore the consequences of the interaction of PLGA and pSi NPs with DCs. In 
order to perform these investigations, we started a collaboration with two research 
groups of Verona University, that produced and characterized NPs. The PLGA NPs used in 
this work, characterized by an uniform size (diameter about 100-150 nm) and a negative 
charge, have been kindly provided by Dr H. Monaco. The pSi NPs used in this work have 
been provided by Dr. N. Daldosso. The group of Dr. Daldosso produced pSi NPs with NH2 
or COOH groups on their surface, leading to a different electric charge. Moreover, this 
group characterized the optical properties of these NPs. The final size of these particles is 
highly heterogeneous as it is due to the random aggregation of various small pSi NPs. 
Importantly, all the results obtained by treating DCs with pSi-NH2 or pSi-COOH are 
completely comparable demonstrating that the presence of NH2 or COOH is irrelevant for 
pSi NPs-DCs interaction. 
A major problem holding back the use of particles in targeted drug delivery is the 
ability of some of them to activate immune cells, thus evoking pro-inflammatory effects 
that hinder their use for in vitro experiments, and in vivo can lead to adverse reactions 
such as fever, allergy or autoimmunity. These effects can be ascribed to interactions 
between particle components and immune cell structures, as well as to microorganisms 
or their derivatives contaminating the particles and engaging pattern recognition 
receptors (PRRs) on the cell surface. The results of this second part of the work clearly 
show that both PLGA and pSi NPs do not affect the DC viability. However while the 
treatment of DCs with extremely high doses of pSi NPs does not affect cell viability, high 
doses of PLGA NPs result to be quite toxic. Nevertheless, it is important to note that the 
toxic effect of PLGA NPs on DCs has been observed upon cell treatment with amounts of 
particles which are unusually high for in vitro DC stimulation.  
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The data obtained herein show that both PLGA and pSi NPs are unable to activate 
a substantial cytokine production by resting DCs, thus ruling out the possibility of particle-
mediated stimulatory effects as well as an eventual their contamination by 
microorganisms. Moreover, the PLGA and pSi NPs do not affect the cytokine production 
by LPS-stimulated DCs, indicating that also in the presence of a pro-inflammatory agent, 
these NPs are immunologically inert and harmless.  
Several studies on PLGA NPs have shown that these structures can entrap a wide 
range of biologically active compounds and are able to enter inside the cells where they 
release the loaded molecules [106].  Conversely, little is known about the ability of pSi 
NPs to be internalized by human primary cells. Indeed, the few data published on this 
matter have been obtained using pSi particles having sizes and functionalizations different 
from those presented in this work [105, 106]. The confocal microscopy analyses 
performed herein demonstrate that both PLGA and pSi NPs are taken up by human DCs. 
However, our results demonstrate that PLGA NPs are more efficiently internalized by DCs 
than pSi NPs. Our findings are in line with previous reports showing that PLGA particles 
could be easily ingested by human moDCs [107], human cord -blood CD34+ stem cells-
derived DCs [108]  and mouse bone marrow-derived DCs [109]. 
The discrepancy between pSi and PLGA NPs internalization by human DCs could be 
ascribed to their different chemical nature and/or to their size. It’s important to underline 
that PLGA NP size is well defined, whereas small pSi NPs can easily aggregate producing 
particles with heterogeneous sizes, becoming too big to be taken up by DCs or being too 
small to remain inside the cells. 
Some authors suggest the PLGA NPs are preferentially taken up by both human 
and mouse DCs rather than by other cell types [107-109]. However, we performed control 
experiments in which HUVEC cells have been treated with PLGA NPs, and we found that 
these endothelial cells efficiently internalized PLGA NPs (data not shown). These results 
suggest that in our experimental conditions the uptake of PLGA NPs by human moDCs is 
not selective, pointing out the necessity to attach a specific DC-recognizing antibody on 
NP surface. This point will be the subject of future investigations. 
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In conclusion, considering their scarce toxicity, their low ability to modulate the 
immune response and their good internalization by human moDCs, we believe that PLGA 
NPs could be a good tool to be used for targeting molecules into human DCs.  
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4. CONCLUSION 
 
The results reported in this study demonstrate that HspX and ESAT-6 cooperate to 
enhance the capacity of human BCG-primed DCs to produce IL-12 which, in turn, induces 
an effective Th1 and NK cell response. These findings suggest that the combination of 
antigens and bacteria investigated by us could be used to increase the immune system’s 
responsiveness to vaccination with BCG. Moreover in this work we identified and tested 
a nano delivery system based on PLGA NPs that could improve the capture of 
BCG/HspX/ESAT-6 by human moDCs. Collectively these results suggest a new vaccination 
strategy against TB based on i) the combination of BCG/HspX/ESAT-6 in order to stimulate 
the immune system, and ii) the use of PLGA NPs to target antigens into human DCs. 
 Of course, our in vitro model needs to be tested also in vivo. Moreover, further 
experiments are ongoing in order to develop a suitable protocol to encapsulate 
BCG/HspX/ESAT-6 into PLGA NPs. 
 
In conclusion, the results of the investigations reported herein on DC-mediated 
immune response could improve our knowledge in the field of TB vaccine and could lead 
to the development of vaccine formulations suitable to efficiently prevent this re-
emerging disease. Furthermore, the strategy presented herein could be easily extended 
to other experimental approaches based on DC targeting, i.g. cancer immunotherapy via 
DCs. 
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5. Appendix 1: ABBREVIATIONS  
 
Ab: antibody 
APCs: antigen presenting cells 
BCG: Bacillus Calmette-Guerin 
BFA: brefeldin A 
CD: cluster of Differentiation marker 
CFP-10: culture filtrate protein 10 KDa 
CLRs: C-type lectin receptors 
CRDs: carbohydrate recognition domains 
DCs: dendritic cells 
DC-SIGN:  dendritic cell-specific intercellular cell adhesion molecule grabbing non-integrin 
Dectin-1: dendritic-cell-associated C-type lectin-1 
ELISA: enzyme linked immuno sorbent assay 
ESAT-6: early secreted antigen target 6 KDa 
FACS: fluorescence-activated cell sorter 
FC: fold Change 
FDA: food and drug administration 
GATA3: GATA binding protein 3 
GM-CSF: granulocyte-macrophages colony-stimulating factor 
HLA: human leukocyte antigen 
HspX: heat shock protein X 
HUVEC: human umbilical vein endothelial cell 
iDCs: immature dendritic cells 
IFNs: interferons  
Ig: immunoglobulin 
IL: interleukin 
LPS: lipopolysaccharide 
mDCs: mature dendritic cells 
MHC: major histocompatibility complex 
moDCs: monocyte-derived Dendritic Cells 
Mtb: Mycobacterium tuberculosis H37 Rv 
NF-kB: nuclear factor κappa B 
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NPs: nanoparticles 
Pam3CSK4 : palmitoyl-3-Cysteine-Serine-Lysine-4  
PAMPs : pathogen-associated molecular pattern 
PBMC: peripheral blood mononuclear cells 
PLGA: poly lactic-co-glycolic acid 
PMN: polymorphonuclear neutrophils 
pSi: porous Silicon 
PRRs:  pattern recognition receptors 
RD1: region of difference-1 
RNA: ribonucleic acid 
pSi: porous silicon 
SD: standard deviation 
Th: T helper lymphocytes 
TB: tuberculosis  
T-bet: T-box expressed in T cells 
TGF: transforming growth factor  
TLRs: Toll-Like Receptor 
TNF-α: tumor necrosis factor α 
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6. APPENDIX 2: Pubblications 
 
The results of the studies conducted during my PhD, including those presented in this 
thesis, have been published in international scientific journals. In this appendix the list of 
my publications and of the manuscripts submitted or in preparations is reported.  
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